Impella Sales Drive Abiomed F2016 Q2 Revenues Up 47%
This article was originally published in Clinica
Abiomed’s Protected PCI initiative, an effort to make the company’s Impella line of percutaneous heart pumps part of the standard of care for intervention in high risk patients, is off to a good start with 70% procedure growth in the US during the second fiscal quarter of 2016.
You may also be interested in...
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions each month. This edition includes entries from a variety of companies and technologies, including many post-market studies following regulatory approvals.
Digital Surgery, a London-based developer of surgical artificial intelligence, analytics, digital education and training solutions, will join Medtronic’s surgical robotics business within its minimally invasive therapies group.
In this edition of Device Week, Medtech Insight's managing editor Marion Webb talks with deputy editor Reed Miller about his recent story on Abiomed's plan to counter unfavorable studies of its Impella heart pump.
[Editor's note: This article was updated on 14 February 2020 to clarify that Abiomed has invested more than $100m over the past five years in clinical research on the Impella heart pump platform. Abiomed has not committed to spend another $100m on new physician education and communication programs.]